Hint mode is switched on Switch off
For swift navigation between sections

Travere Therapeutics

PDF download

Choose all Reset all
Download Cancel
Organization name
Travere Therapeutics Inc (formerly Retrophin Inc)
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
791 mln USD

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Retrophin Inc. (Retrophin), formerly Desert Gateway, Inc., is a biotechnology company. The Company focused on discovering and developing treatments for rare and life-threatening diseases. The Company is developing treatments for Focal Segmental Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN), Duchenne Muscular Dystrophy and other catastrophic diseases. 

Awards

News

03/06/2026 Travere Therapeutics (NASDAQ: TVTX) Gains Analyst Confidence Amidst New Kidney Disease Drug Partnership
01/06/2026 Travere Therapeutics: Entry Into A Material Definitive Agreement, Financial Statements And Exhibits
12/05/2026 New issue: Travere Therapeutics issued international bonds (US89422GAB32) with the coupon rate of 0.5% in the amount of USD 475 mln maturing in 2032
06/05/2026 Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
06/05/2026 Upcoming Issue: Travere Therapeutics
All organization news

Documentation

IFRS/US GAAP reports

2026
I q eng
2025
I q eng
II q eng
III q eng
IV q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Latest issues

Show all

Public debt by currencies

Show more Hide

Codes

  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • CIK
    0001438533
  • EIN
    26-2383102
Registration is required to get access.